Strategies for the Prevention of Late CMV Infections After SCT
M. Boeckh
Seattle, USA
Proteomics for Early Prediction of GVHD and CMV Infection
E. M. Mischak-Weissinger
Hannover, Germany
Use of Antiviral Agents Against Other Herpesvirus Infections After SCT
P. Ljungman
Stockholm, Swedenam
 |
Extracorporeal Photopheresis Mechanism of Action in GvHD Francine Foss, MD Tufts New England Medical Center Extracorporeal Photopheresis as Part of a Standard Myeloablative Preparative Regimen to Prevent Acute GvHD Paul Shaughnessy, MD Texas Transplant Institute ECP in Skin and Liver GvHD: The MDACC Experience Daniel Couriel, MD M.D. Anderson Cancer Center |
Advances in Intravenous Immunoglobulin Therapy: Mechanisms of Action and Clinical Applications
Ronald A. Sacher, MD
University of Cincinnati Medical Center
Confronting the New Challenges in Blood Product Pathogen Safety
Dominique Pifat, PhD
Bayer Corporation, Biological Products Division
Role of FC Receptors in Autoimmune Disease and their Modulation by Intravenous Gammaglobulin
Jeffrey V. Ravetch, MD, PhD
The Rockefeller University
Comparison of Different IGIV Preparations in the
Normalization of Platelet Counts in ITP
Anne L. Angiolillo, MD
George Washington University School of Medicine and Health Sciences
Recognizing the Differences in IGIV Production-from Efficacy to Tolerability
Erwin W. Gelfand, MD
University of Colorado Health Sciences Center
Chairman, Department of Pediatrics
Questions & Answers
 |
Extracorporeal Photopheresis in the Prevention of GvHD Francine Foss, MD Tufts New England Medical Center Extracorporeal Photopheresis for the Management of Cutaneous Chronic GvHD Paolo Anderlini, MD University of Texas MD Anderson Cancer Center Extracorporeal Photochemotherapy for Pediatric Patients with Acute and Chronic GvHD Roberto Dall'Amico, MD, PhD University of Padua School of Medicine Question & Answer Session |
Copyright © 1995-2008 Carden Jennings Publishing Co., Ltd. All rights reserved.